Protara Therapeutics, Inc. financial data

Symbol
TARA on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1486% % 27%
Debt-to-equity 8% % -42%
Return On Equity -35% % 37%
Return On Assets -32% % 34%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38,587,260 shares 87%
Common Stock, Shares, Outstanding 38,587,260 shares 87%
Entity Public Float $35,000,000 USD 94%
Common Stock, Value, Issued $39,000 USD 86%
Weighted Average Number of Shares Outstanding, Basic 42,272,104 shares 89%
Weighted Average Number of Shares Outstanding, Diluted 42,272,104 shares 89%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $39,008,000 USD 36%
General and Administrative Expense $20,774,000 USD 20%
Operating Income (Loss) $59,782,000 USD -30%
Nonoperating Income (Expense) $6,881,000 USD 79%
Net Income (Loss) Attributable to Parent $52,901,000 USD -26%
Earnings Per Share, Basic -1 USD/shares 57%
Earnings Per Share, Diluted -1 USD/shares 57%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $12,551,000 USD -76%
Marketable Securities, Current $120,119,000 USD 304%
Other Assets, Current $218,000 USD 7167%
Assets, Current $135,644,000 USD 59%
Property, Plant and Equipment, Net $828,000 USD -25%
Operating Lease, Right-of-Use Asset $3,452,000 USD -24%
Other Assets, Noncurrent $21,000 USD -36%
Assets $144,636,000 USD 54%
Accounts Payable, Current $4,504,000 USD 96%
Employee-related Liabilities, Current $2,244,000 USD
Accrued Liabilities, Current $4,185,000 USD -21%
Liabilities, Current $9,909,000 USD 15%
Operating Lease, Liability, Noncurrent $2,436,000 USD -33%
Liabilities $12,345,000 USD 0.37%
Accumulated Other Comprehensive Income (Loss), Net of Tax $143,000 USD 393%
Retained Earnings (Accumulated Deficit) $285,112,000 USD -23%
Stockholders' Equity Attributable to Parent $132,291,000 USD 62%
Liabilities and Equity $144,636,000 USD 54%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,713,000 USD -42%
Net Cash Provided by (Used in) Financing Activities $1,730,000 USD
Net Cash Provided by (Used in) Investing Activities $58,354,000 USD -353%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 38,587,260 shares 87%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,296,000 USD -75%
Deferred Tax Assets, Valuation Allowance $72,500,000 USD 38%
Deferred Tax Assets, Gross $74,265,000 USD 37%
Operating Lease, Liability $3,656,000 USD -23%
Depreciation $83,000 USD 0%
Payments to Acquire Property, Plant, and Equipment $44,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $52,787,000 USD -26%
Lessee, Operating Lease, Liability, to be Paid $4,020,000 USD -25%
Property, Plant and Equipment, Gross $2,133,000 USD 0.61%
Operating Lease, Liability, Current $1,220,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,429,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,429,000 USD 2.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $364,000 USD -44%
Lessee, Operating Lease, Liability, to be Paid, Year Three $718,000 USD -50%
Deferred Tax Assets, Operating Loss Carryforwards $37,195,000 USD 21%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $87,000 USD -88%
Operating Lease, Payments $332,000 USD 0%
Additional Paid in Capital $417,221,000 USD 33%
Deferred Tax Assets, Net of Valuation Allowance $1,756 USD
Share-based Payment Arrangement, Expense $4,673,000 USD -23%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%